Skip to main content
Premium Trial:

Request an Annual Quote

Lester Crawford, Steven Galson, Janet Woodcock, David Thompson, Lance Fors, James Connelly, Robert Ragusa, R. Scott Greer, Christine Chung, Fred Gage, Inder Verma, Richard Gregory, NanoDrop, Agilent, BioGenex, Sigma-Aldrich

Premium

Pairings

US Food and Drug Administration Commissioner Lester Crawford has appointed Steven Galson to be director of the FDA's Center for Drug Evaluation and Research, the agency said in a statement this week.

Galson, a rear admiral in the commissioned corps of the US Public Health Service, had most recently served as acting center director, and formerly served as deputy director since he joined the FDA in 2001. Galson holds a BS from Stony Brook University, an MD from the Mt. Sinai School of Medicine and an MPH from the Harvard School of Public Health.

Galson replaces Janet Woodcock as director of the CDER. Woodcock has been named deputy commissioner for operations and chief operating officer at the FDA, Crawford said.


David Thompson has been elected chairman of the board of directors at Third Wave Technologies, the company said this week.

Thompson previously served as the senior vice president and president of the diagnostic division of Abbott Laboratories. He also serves as a director of St. Jude Medical, the global medical device company.

Thompson replaces Third Wave co-founder Lance Fors, who has resigned from his position and will remains as a technology adviser to the company.

Third Wave also has added James Connelly to its board of directors. Connelly is a partner in the Foley & Lardner law firm. Connelly was selected as a White House fellow by President Gerald Ford and served subsequently as special assistant to Treasury Secretary William Simon in that administration.

Connelly holds a BA from Marquette University and his law degree from the Georgetown University Law Center.


Robert Ragusa joined Affymetrix as senior vice president of global operations on June 27, Pharmacogenomics Reporter sister publication GenomeWeb News has learned. He comes to Affy from Applied Biosystems, where he was senior vice president of global operations. He left ABI in March.

According to an Affymetrix spokesman, the company created Ragusa's position to help increase its attention to supply chain and logistics. He will oversee areas such as array manufacturing, instrument manufacturing, procurement, facilities and real estate. Ragusa holds an MBA in finance and marketing from the University of Connecticut, a master's degree in biomedical and electrical engineering from Carnegie-Mellon University, and a bachelor's degree in biomedical and electrical engineering from the University of Connecticut.


R. Scott Greer has joined CombiMatrix as an advisor, the company said this week. Greer is the managing director of Numenor Ventures, a life sciences investment and advisory firm. He is the founder and chairman of AbiGenix, where he served as CEO from 1996 to 2002. Greer also served as a director at Illumina, Sirna Therapeutics, and CV Therapeutics.

He holds an MBA from Harvard University and a BA in economics from Whitman College.


Christine Chung has been awarded a five-year, $750,000 grant from the Damon Runyon Cancer Research Foundation, according to a report in the Nashville City Paper. She is an assistant professor of medicine in the division of hematology and oncology at Vanderbilt University. Chung will be using microarray technology to develop gene expression patterns and biomarkers for diagnosis and treatment of head and neck cancers, according to the report.


Fred Gage, Inder Verma, and Richard Gregory have been added to the scientific advisory of RheoGene, the Norristown, Penn.-based company said yesterday.

Gage currently is a professor in the Laboratory of Genetics at the Salk Institute and member of the National Academy of Sciences, the company said, while Gregory, serves as senior vice president and head of research at Genzyme.

Verma serves as director of the Laboratory of Genetics at the Salk Institute and adjunct professor in the department of biology at UC San Diego. Verma is also a member of the National Academy of Sciences and past president of the American Society for Gene Therapy, RheoGene said.


As of this week, Genome Canada's board includes Natalie Dakers, the CEO of British Columbia's Centre for Drug Research and Development; Connie Eaves a professor of medicine at the University of British Columbia; Thomas Hudson, the director of the McGill University and Genome Quebec Innovation Centre and a past assistant-director of the Whitehead Institute/MIT Center for Genome Research; Kelvin Ogilvie, a professor of chemistry at Acadia University in Nova Scotia; Jacques Simard, the director of the Cancer Genomics Laboratory at Centre Hospitalier Universitaire de Québec; and Ronald Worton, the CEO and scientific director for the Ottawa Health Research Institute.

New Releases

NanoDrop Technologies last month launched its ND-3300 fluorospectrometer, which is capable of "pushing the sensitivity of nucleic acids and microarray dyes" beyond competitive technologies and provides the "benefits of measuring two picograms of DNA in a two microliter PicoGreen [assay] reaction," according to a statement from the company.


Agilent Technologies last week announced that eArray 3.5, an upgrade from the eArray 3.0 web-based tool it launched earlier this year for designing custom DNA microarrays used in drug discovery, disease studies and basic research.

eArray 3.5 enables the sharing of microarray design information among collaborators or with members of research consortia via secure Internet connections, Agilent said.

The 3.5 upgrade also allows access to catalog array comparative genomic hybridization probes, and has been reconfigured to permit researchers to upload their own aCGH probes into the system. The free tool is available on Agilent's website.


BioGenex last month launched its Xmatrx system, which it describes as being ideal for automation of fluorescent in situ hybridization, in situ hybridization, and immunohistochemistry experiments.

Xmatrx is recommended for use in molecular diagnostics and drug research and development, according to a statement from the company.


Sigma-Aldrich last month launched a mitogen-activated protein kinase (MAPK) antibody array and an antibody array for protein kinase C (PKC) expression in cell or protein extracts, the company said.

The company also introduced its Panorama Ab Microarray — MAPK & PKC Pathways Kit, which it recommends for "studying protein expression in cell or tissue extracts" and said is "compatible with various species including human, mouse, and rat."

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.